GlassScriptPhysician profile
Lisa A Dugger
NPI 1083615868
$3,258.09
in general payments reported to CMS, 2019-2025
24 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $509 · 2023: $895 · 2024: $1,181 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $799.60 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $496.06 | 2022-2025 | Watchman Flx, Farapulse, Watchman Access System |
| Amgen INC. | $398.58 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $304.02 | 2022-2025 | |
| Abbott Laboratories | $214.86 | 2021-2024 | Xience Skypoint |
| Atricure, INC. | $148.49 | 2024 | |
| Cvrx, INC. | $118.54 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $108.84 | 2022 | |
| Pfizer INC. | $84.64 | 2022-2025 | |
| Inspire Medical Systems, INC. | $80.13 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $71.78 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $61.00 | 2022-2024 | Xarelto |
| Abiomed | $55.91 | 2023 | Impella |
| Heartflow, INC. | $55.71 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $36.17 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $33.34 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $33.31 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $29.66 | 2024 | Eliquis, Camzyos |
| Medtronic, INC. | $27.09 | 2024 | Micra |
| Kiniksa Pharmaceuticals International, Plc | $25.71 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $24.98 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.08 | 2022 | |
| Edwards Lifesciences Corporation | $16.55 | 2025 | |
| Philips North America LLC | $15.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Dugger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.